HENDERSON MICHAEL THOMAS 4
4 · Apogee Therapeutics, Inc. · Filed Apr 10, 2026
Research Summary
AI-generated summary of this filing
Apogee (APGE) CEO Michael Henderson Sells Shares
What Happened
Michael T. Henderson, CEO of Apogee Therapeutics (APGE), sold a total of 20,000 common shares in open-market transactions on April 8, 2026, for aggregate proceeds of approximately $1,651,664. The sales consisted of 17,800 shares at a reported weighted average price of $82.48 (F2) for $1,468,144; 2,000 shares at a reported weighted average price of $83.26 (F3) for $166,520; and 200 shares at $85.00 for $17,000. These were dispositions (sales), not purchases.
Key Details
- Transaction date: 2026-04-08; Form 4 filed: 2026-04-10 (appears timely).
- Trade details:
- 17,800 shares sold — reported $82.48 weighted avg; prices ranged $82.00–$82.97 (F2) — $1,468,144.
- 2,000 shares sold — reported $83.26 weighted avg; prices ranged $83.00–$83.50 (F3) — $166,520.
- 200 shares sold — $85.00 — $17,000.
- Total: 20,000 shares sold for $1,651,664.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnotes: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted Aug 13, 2025 (F1). F2 and F3 note weighted-average pricing and per-price ranges; the reporting person can provide per-price counts on request.
Context
- Sales under a Rule 10b5-1 plan are typically prearranged, which can indicate the trades were scheduled in advance rather than reflecting new private information. This is a routine insider sale rather than a purchase (which investors often view as a stronger bullish signal).
Insider Transaction Report
Form 4
HENDERSON MICHAEL THOMAS
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-04-08$82.48/sh−17,800$1,468,144→ 1,135,187 total - Sale
Common Stock
[F1][F3]2026-04-08$83.26/sh−2,000$166,520→ 1,133,187 total - Sale
Common Stock
[F1]2026-04-08$85.00/sh−200$17,000→ 1,132,987 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.00 to $82.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.00 to $83.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Matthew Batters, as attorney-in-fact for Michael Henderson|2026-04-10